FLI1 and Ewing sarcoma: Another small molecule, YK-4-279, is able to disrupt binding between fusion protein EWS-FLI1, specific for Ewing's sarcoma [17], and RNA Helicase A (RHA), which is necessary to enhance the oncogenic activity of EWS-FLI1 [18].